-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora Therapeutics Begins Phase 1 Clinical Trial Of NMRA-861, A Selective M4 Positive Allosteric Modulator For Schizophrenia

Benzinga·07/09/2025 11:08:05
Listen to the news
  • NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile
  • No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits